Canaccord Genuity Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $35

Benzinga Newsdesk www.benzinga.com Neutral 53.1%

Neg 0% Neu 53.1% Pos 0%

Canaccord Genuity analyst Sumant Kulkarni initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $35.